DE69737062D1 - Gentherapie für kongestives herzversagen - Google Patents

Gentherapie für kongestives herzversagen

Info

Publication number
DE69737062D1
DE69737062D1 DE69737062T DE69737062T DE69737062D1 DE 69737062 D1 DE69737062 D1 DE 69737062D1 DE 69737062 T DE69737062 T DE 69737062T DE 69737062 T DE69737062 T DE 69737062T DE 69737062 D1 DE69737062 D1 DE 69737062D1
Authority
DE
Germany
Prior art keywords
heart failure
congestive heart
gene therapy
present
myocardium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69737062T
Other languages
English (en)
Other versions
DE69737062T2 (de
Inventor
Kirk Hammond
A Insel
Peipei Ping
R Post
Meihua Gao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Collateral Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, Collateral Therapeutics Inc filed Critical University of California
Application granted granted Critical
Publication of DE69737062D1 publication Critical patent/DE69737062D1/de
Publication of DE69737062T2 publication Critical patent/DE69737062T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1787—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69737062T 1996-09-05 1997-09-05 Gentherapie für kongestives herzversagen Expired - Lifetime DE69737062T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US70866196A 1996-09-05 1996-09-05
US708661 1996-09-05
US4893397P 1997-06-16 1997-06-16
US48933P 1997-06-16
PCT/US1997/015610 WO1998010085A2 (en) 1996-09-05 1997-09-05 Gene therapy for congestive heart failure

Publications (2)

Publication Number Publication Date
DE69737062D1 true DE69737062D1 (de) 2007-01-18
DE69737062T2 DE69737062T2 (de) 2007-07-12

Family

ID=26726691

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69737062T Expired - Lifetime DE69737062T2 (de) 1996-09-05 1997-09-05 Gentherapie für kongestives herzversagen

Country Status (9)

Country Link
EP (1) EP0934422B1 (de)
JP (1) JP2002514908A (de)
CN (1) CN1234835A (de)
AT (1) ATE347606T1 (de)
AU (1) AU741931B2 (de)
CA (1) CA2262406C (de)
DE (1) DE69737062T2 (de)
EA (1) EA199900261A1 (de)
WO (1) WO1998010085A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA001616B1 (ru) 1995-02-28 2001-06-25 Зе Риджентс Оф Зи Юнивесити Оф Кэлифоньэ Способ лечения болезни сердца, способ лечения недостаточности периферических сосудов и способ ограничения доставки и экспрессии трансгенной конструкции в определенном органе или структуре
IL125756A (en) 1996-02-15 2003-05-29 Biosense Inc Catheter for use in surgery
US6465237B1 (en) 1997-07-01 2002-10-15 Millennium Pharmaceuticals, Inc. Cloning and characterization of a human adenylyl cyclase
WO1999001547A1 (en) * 1997-07-01 1999-01-14 Cor Therapeutics, Inc. Cloning and characterization of a human adenylyl cyclase
DE69838526T2 (de) 1998-02-05 2008-07-03 Biosense Webster, Inc., Diamond Bar Gerät zum Freisetzen eines Medikaments im Herzen
WO1999062940A2 (en) * 1998-05-30 1999-12-09 Collateral Therapeutics, Inc. Methods of altering cardiac cell phenotype
IT1308613B1 (it) 1999-02-17 2002-01-09 Pharmacia & Upjohn Spa Acidi grassi essenziali nella prevenzione di eventi cardiovascolari.
WO2001048164A2 (en) 1999-12-27 2001-07-05 The Regents Of The University Of California Modified adenylylcyclase type vi useful in gene therapy for congestive heart failure
ITMI20010129A1 (it) * 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
US20070265221A1 (en) * 2006-05-09 2007-11-15 Weiss Robert G Methods to improve creatine kinase metabolism and contractile function in cardiac muscle for the treatment of heart failure
CA2705862C (en) * 2007-11-16 2018-03-27 San Diego State University Research Foundation Compositions and method for manipulating pim-1 activity in circulatory system cells
AU2008350903B2 (en) 2008-02-19 2015-04-02 Celladon Corporation Compositions for enhanced uptake of viral vectors in the myocardium

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5334521A (en) * 1991-11-18 1994-08-02 American Cyanamid Company Cloning and characterization of a cardiac adenylyl cyclase
US6034071A (en) * 1994-09-16 2000-03-07 Iyengar; Srinivas Ravi V. Mutant activated GS α and adenylyl cyclase 2 for use as therapeutic agents
WO1997016169A1 (en) * 1995-11-01 1997-05-09 Chiron Corporation Treatment of a cardiovascular indication by delivery of therapeutics to the pericardial space
DE19681032D2 (de) * 1995-11-17 1999-04-08 Franz Wolfgang M Dr Gentherapeutisches Nukleinsäurekonstrukt, seine Herstellung und Verwendung zur Behandlung von Herzerkrankungen

Also Published As

Publication number Publication date
DE69737062T2 (de) 2007-07-12
AU4251997A (en) 1998-03-26
WO1998010085A2 (en) 1998-03-12
CA2262406A1 (en) 1998-03-12
ATE347606T1 (de) 2006-12-15
JP2002514908A (ja) 2002-05-21
WO1998010085A3 (en) 1998-05-14
EA199900261A1 (ru) 1999-10-28
EP0934422B1 (de) 2006-12-06
AU741931B2 (en) 2001-12-13
CN1234835A (zh) 1999-11-10
CA2262406C (en) 2010-12-07
EP0934422A2 (de) 1999-08-11

Similar Documents

Publication Publication Date Title
NO962791L (no) Preparater inneholdende nukleinsyrer, deres fremstilling og anvendelse
DE69737062D1 (de) Gentherapie für kongestives herzversagen
AU2789989A (en) Acylated uridine and cytidine and uses thereof
WO1999040197A3 (en) Variants of the angiogenic factor vascular endothelial cell growth factor: vegf
GR3026129T3 (en) Methods and diagnostic kits utilizing mammalian stress promoters to determine toxicity of a compound.
DE69929810D1 (de) Verwendung von tetracyclinderivaten zur steigerung der interleukin-10 produktion
EA200000926A1 (ru) Экспрессия генов биосинтеза трегалозы в растениях
NO971341D0 (no) Promoter for reseptor tyrosinkinase TIE
PT851926E (pt) Variantes do interferao-gama (rhu-ifn-gama) recombinante humano com estabilidade termica melhorada
EA200500934A1 (ru) Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний
BR9811014A (pt) "região concentrada reguladora de gene especìfica para semente precoce"
WO2001048164A3 (en) Modified adenylylcyclase type vi useful in gene therapy for congestive heart failure
DK0655926T3 (da) Ny sonde til tumordiagnose eller tumorterapi
FI864597A (fi) Kardiotoniska tiazoloner.
DE69529750D1 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
EA199700243A1 (ru) Производное аминотетралина для лечения сердечно-сосудистых заболеваний
DE69929683D1 (de) Antisense modulierung von lfa-3
FI980902A (fi) Levosimendaanin stabiileja koostumuksia
ATE79615T1 (de) Cardiotonische phenyloxazolone.
DE59904870D1 (de) Antisense-sequenzen für die hemmung der expression des adhäsionsmoleküls icam-1
PT870015E (pt) Novas xilanases os genes que as codificam e as suas utilizacoes
NZ515727A (en) Aminotetralin derivative for the therapy of cardiovascular diseases
PT925064E (pt) 5-androsteno-3beta,17alfa-diol como um inibidor do crescimento tumoral
ATE42201T1 (de) Verwendung von phytosterolglycosiden zur herstellung von arzneimitteln zur behandlung von erhoehtem 5(6)alpha-epoxycholesterolgehalt.
ATE69609T1 (de) Cardiotonische imidazolylphenylpyrrol-2-one.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R081 Change of applicant/patentee

Ref document number: 934422

Country of ref document: EP

Owner name: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, US

Free format text: FORMER OWNER: THE REGENTS OF THE UNIVERSITY O, COLLATERAL THERAPEUTICS, , US

Effective date: 20120830

R082 Change of representative

Ref document number: 934422

Country of ref document: EP

Representative=s name: WUESTHOFF & WUESTHOFF PATENT- UND RECHTSANWAEL, DE

Effective date: 20120830